Nature Medicine, Published online: 16 September 2026; doi:10.1038/s41591-026-04636-8

In this single-arm phase 1 trial, an AAV gene therapy carrying the Padua variant of factor IX was well tolerated in 11 adolescents with hemophilia B and led to reductions in annualized bleeding rate.

arXiv:2511.08887v4 Announce Type: replace-cross Abstract: Stroke is an acute cerebrovascular disease, and timely diagnosis significantly improves patient survival. However, existing automated diagnosis methods suffer from fairness issues across demographic groups, potentially exacerbating healthcare disparities. In this work we propose FAST-CAD, a theoretically grounded framework that combines domain-adversarial training (DAT) with group distributionally robust optimization (Group-DRO) for fair and accurate non-contact stroke diagnosis. Our approach is built on domain adaptation and minimax fairness theory and provides convergence guarantees and fairness bounds. We curate a multimodal dataset covering 12 demographic subgroups defined by age, gender, and posture. FAST-CAD employs self-supervised encoders with adversarial domain discrimination to learn demographic-invariant representations, while Group-DRO optimizes worst-group risk to ensure robust performance across all subgroups. Extensive experiments show that our method achieves superior diagnostic performance while maintaining fairness across demographic groups, and our theoretical analysis supports the effectiveness of the unified DAT + Group-DRO framework. This work provides both practical advances and theoretical insights for fair medical AI systems.

Cell Death Discovery, Published online: 31 March 2026; doi:10.1038/s41420-026-03014-0

Doxorubicin promotes the production of inflammatory cytokines in tumor-associated macrophages through activating lactate dehydrogenase A

Oncogene, Published online: 23 March 2026; doi:10.1038/s41388-026-03734-8

PAK4 functions as an immune suppressor by reprogramming the phosphatidylcholine metabolism of CD8 + T cells within the glioblastoma tumor microenvironment

arXiv:2601.11895v2 Announce Type: replace-cross Abstract: DevBench is a telemetry-driven benchmark designed to evaluate Large Language Models (LLMs) on realistic code completion tasks. It includes 1,800 evaluation instances across six programming languages and six task categories derived from real developer telemetry, such as API usage and code purpose understanding. Unlike prior benchmarks, it emphasizes ecological validity, avoids training data contamination, and enables detailed diagnostics. The evaluation combines functional correctness, similarity-based metrics, and LLM-judge assessments focused on usefulness and contextual relevance. 9 state-of-the-art models were assessed, revealing differences in syntactic precision, semantic reasoning, and practical utility. Our benchmark provides actionable insights to guide model selection and improvement-detail that is often missing from other benchmarks but is essential for both practical deployment and targeted model development.